VGX 3400

Drug Profile

VGX 3400

Alternative Names: VGX-3400X; VGX™-3400

Latest Information Update: 18 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Pennsylvania
  • Developer GeneOne Life Science; Inovio Pharmaceuticals
  • Class DNA vaccines; Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype

Most Recent Events

  • 16 May 2012 Final immunogenicity data from a phase I extension trial in Influenza-A virus subtype H5N1 infections (prevention) released by Inovio Pharmaceuticals
  • 16 May 2012 Inovio Pharmaceuticals completes a phase I trial in Influenza-A virus H5N1 subtype infections (Prevention, In volunteers) in USA (9137178; NCT01142362 and NCT01403155)
  • 17 Nov 2011 Interim immunogenicity and adverse events data from a phase I extension trial for Influenza A virus H5N1 subtype infections (Prevention, In volunteers) presented at the 5th WHO Meeting on Influenza Vaccines that Induce Broad Spectrum and Long-Lasting Immune Responses
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top